Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Dyadic, the most common co-covered peer. Precigen appears in 1 tracked Biotech story from March 26, 2026. The tracked stories average 5 original sources each.
Last mentioned: Mar 26, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Dyadic, the most common co-covered peer. Precigen appears in 1 tracked Biotech story from March 26, 2026. The tracked stories average 5 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Precigen. Shared-story counts are live from our verified record — not editorial picks.
Q1 Guidance
Precigen forecasts $18M+ revenue for Q1 2026, a massive sequential jump.
Albumin Commercialization
Dyadic and ProLiant Health launch recombinant albumin for global sales.
FY 2025 Close
Dyadic ends year with $8.6M cash; Paysign hits record $82M annual revenue.
Papzimius Launch
Precigen initiates commercial shipments of Papzimius for adult RRP.
Dyadic and Precigen have successfully transitioned from R&D-focused entities to commercial-stage biotechs, marked by the launch of recombinant albumin and Papzimius respectively. This shift is supported by a robust pharma services sector, as evidenced by Paysign’s record growth in patient affordability programs for top-tier manufacturers.
Precigen is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
